Poly Medicure Ltd. shares declined 6% on Wednesday, May 27, extending losses for the third consecutive session amid investor concerns over margin pressure and geopolitical disruptions. According to reports from CNBC TV18, the stock has fallen nearly 15% over the last three trading sessions, reflecting market uncertainty about the company's near-term profitability outlook.
The company has projected consolidated EBITDA margins of 23-25% for FY27, while standalone margins are expected to remain between 25-27%. As reported by CNBC TV18, management flagged a sharp shift in the external operating environment, describing the current situation as challenging due to ongoing tensions in West Asia. The region contributes around 6-8% of the company's revenue, with export logistics becoming significantly more difficult leading to delays in execution of pending orders.
Despite margin pressures, Poly Medicure continued to report strong operational performance across geographies. According to CNBC TV18, domestic revenue rose 25% year-on-year during Q4FY26, while European revenue increased 23% and the rest-of-world business grew 16.5%. For the full year, domestic revenue expanded nearly 20%, while international business revenue rose over 9%.
The company ended FY26 with a cash balance of ₹842 crore and continued strengthening its global footprint. As reported by CNBC TV18, integration of recent acquisitions is underway, including the acquisition of Medyneo in April 2026, aimed at expanding its presence in the South American market. Management described Brazil as a strategically important market for future growth, with the company launching 35 new products during FY26.
For FY27, Poly Medicure has guided for consolidated revenue in the range of ₹2,300-2,400 crore, driven by expected growth of 20% in the domestic business and 15% growth in international operations. According to CNBC TV18, the company also warned of higher packaging material costs linked to the West Asia conflict, which could result in gross margin erosion of 200-300 basis points going forward. Despite revenue growth, EBITDA margin stood at 21% in Q4FY26 compared to 29.4% in the year-ago quarter.
